258 related articles for article (PubMed ID: 26897009)
21. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
22. Twins in spirit part IV - [
Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J
Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688
[TBL] [Abstract][Full Text] [Related]
23. In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.
Chan HS; de Blois E; Morgenstern A; Bruchertseifer F; de Jong M; Breeman W; Konijnenberg M
PLoS One; 2017; 12(7):e0181473. PubMed ID: 28732021
[TBL] [Abstract][Full Text] [Related]
24. Renal and hematological toxicity in patients of neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-DOTATATE.
Gupta SK; Singla S; Bal C
Cancer Biother Radiopharm; 2012 Nov; 27(9):593-9. PubMed ID: 23009580
[TBL] [Abstract][Full Text] [Related]
25. Additional hepatic
Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
[TBL] [Abstract][Full Text] [Related]
26. Therapy With
Kendi AT; Halfdanarson TR; Packard A; Dundar A; Subramaniam RM
AJR Am J Roentgenol; 2019 Aug; 213(2):309-317. PubMed ID: 31039017
[No Abstract] [Full Text] [Related]
27. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
28. Recognition based hormonal 95kDa monoclonal antibody on three human cancer cell lines for developing targeted radio-immuno-imaging and therapy.
Bandopadhyaya GP; Arora G; Shukla J; Ghosh S
Hell J Nucl Med; 2012; 15(2):108-13. PubMed ID: 22833856
[TBL] [Abstract][Full Text] [Related]
29. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
[TBL] [Abstract][Full Text] [Related]
30. Reduction of renal uptake of radiolabeled octreotate by amifostine coadministration.
Melis M; Valkema R; Krenning EP; de Jong M
J Nucl Med; 2012 May; 53(5):749-53. PubMed ID: 22496587
[TBL] [Abstract][Full Text] [Related]
31. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
[TBL] [Abstract][Full Text] [Related]
32. Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.
Naraev BG; Ramirez RA; Kendi AT; Halfdanarson TR
Clin Lung Cancer; 2019 May; 20(3):e376-e392. PubMed ID: 30910575
[TBL] [Abstract][Full Text] [Related]
33. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
34. Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; de Herder WW; Feelders RA; Krenning EP; Kwekkeboom DJ
Endocr Relat Cancer; 2017 May; 24(5):243-251. PubMed ID: 28320783
[TBL] [Abstract][Full Text] [Related]
35. In Vivo Instability of
Lubberink M; Wilking H; Öst A; Ilan E; Sandström M; Andersson C; Fröss-Baron K; Velikyan I; Sundin A
J Nucl Med; 2020 Sep; 61(9):1337-1340. PubMed ID: 32005767
[TBL] [Abstract][Full Text] [Related]
36. Favorable Response of Metastatic Merkel Cell Carcinoma to Targeted 177Lu-DOTATATE Therapy: Will PRRT Evolve to Become an Important Approach in Receptor-Positive Cases?
Basu S; Ranade R
J Nucl Med Technol; 2016 Jun; 44(2):85-7. PubMed ID: 26471333
[TBL] [Abstract][Full Text] [Related]
37. Protection of Kidney Function with Human Antioxidation Protein α
Kristiansson A; Ahlstedt J; Holmqvist B; Brinte A; Tran TA; Forssell-Aronsson E; Strand SE; Gram M; Åkerström B
Antioxid Redox Signal; 2019 May; 30(14):1746-1759. PubMed ID: 29943622
[TBL] [Abstract][Full Text] [Related]
38. Thymoma treated with 177Lu DOTATATE induction and maintenance PRRT.
Makis W; McCann K; McEwan AJ
Clin Nucl Med; 2015 May; 40(5):e278-81. PubMed ID: 25783505
[TBL] [Abstract][Full Text] [Related]
39. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
[TBL] [Abstract][Full Text] [Related]
40. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with
Hope TA; Abbott A; Colucci K; Bushnell DL; Gardner L; Graham WS; Lindsay S; Metz DC; Pryma DA; Stabin MG; Strosberg JR
J Nucl Med; 2019 Jul; 60(7):937-943. PubMed ID: 31263080
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
